---
title: "Summit Therapeutics Raises $500 Million in Private Placement"
description: "Summit Therapeutics Inc. has raised approximately $500 million through a private placement of 26.68 million shares at $18.74 each. The funds will support the clinical development of ivonescimab and ge"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262236818.md"
published_at: "2025-10-22T12:01:12.000Z"
---

# Summit Therapeutics Raises $500 Million in Private Placement

> Summit Therapeutics Inc. has raised approximately $500 million through a private placement of 26.68 million shares at $18.74 each. The funds will support the clinical development of ivonescimab and general corporate purposes. Company insiders invested $272 million, with Akeso, Inc. contributing $10 million. The remaining $218 million came from various biopharma investors. Summit will file a registration statement with the SEC for share resale.

Summit Therapeutics Inc. has announced it has raised approximately $500 million through a private placement of about 26.68 million shares of its common stock at $18.74 per share. The proceeds will be used to advance the clinical development of ivonescimab, as well as for working capital and general corporate purposes. Company insiders, including Co-CEOs Robert W. Duggan and Dr. Mahkam Zanganeh, along with other executives and employees, invested a combined $272 million. Akeso, Inc., whose CEO Dr. Yu (Michelle) Xia is also a Summit board member, participated with a $10 million investment. The remaining $218 million was raised from multiple leading biopharma institutional and individual investors. Summit has agreed to file a registration statement with the SEC to register the resale of the shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251022041844) on October 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [SMMT.US - Summit Therapeutics](https://longbridge.com/en/quote/SMMT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 民主党阻止拨款法案通过 美国土安全部面临停摆 | 美国参议院民主党人投票阻止一项为国土安全部提供资金的拨款法案，导致该部门面临停摆。投票结果为 52 票赞成、47 票反对，未能达到推进法案所需的 60 票。停摆将影响多个关键机构，包括联邦紧急事务管理局和运输安全管理局。参议院共和党计划提出 | [Link](https://longbridge.com/en/news/275824701.md) |
| 在人工智能时代，人类技能尤为重要：全球研究表明，学生的关键能力提升幅度高达 72% | 诺德安格利亚教育集团的一项全球研究显示，在人工智能驱动的世界中，学生可以提升多达 72% 的关键人类技能。该研究涉及来自 20 个国家 29 所学校的超过 12,000 名学生，强调了合作、好奇心、创造力和批判性思维等技能的重要性，这些是人 | [Link](https://longbridge.com/en/news/275770798.md) |
| SpyGlass Pharma 董事 Bilal Arshad Khan 报告收购普通股 | Bilal Arshad Khan，Spyglass Pharma Inc. 的一名董事，已报告收购该公司的普通股。完整的文件可通过提供的链接获取。此消息由公共技术生成，仅供参考，不应视为财务、投资或法律建议。Spyglass Pharma | [Link](https://longbridge.com/en/news/275656992.md) |
| 印度的人工智能峰会在新德里开幕，但因长队和混乱而受到影响 | 印度在新德里的人工智能影响峰会在开幕当天遭遇了重大批评，原因是长时间排队、拥挤和组织问题。与会者报告称入场程序混乱、指示不明确以及座位不足，许多人无法参加会议。此次活动旨在突出印度的技术雄心，并放大发展中国家在人工智能治理中的声音，但有可能 | [Link](https://longbridge.com/en/news/276061032.md) |
| F5 公司执行副总裁兼总法律顾问 Angelique M. Okeke 报告了普通股的出售 | Angelique M. Okeke，F5 Inc. 的执行副总裁兼总法律顾问，已报告出售该公司的普通股。完整的文件可通过提供的链接获取。此新闻简报由公共技术公司生成，仅供信息参考，不应被视为财务、投资或法律建议。F5 Inc. 于 202 | [Link](https://longbridge.com/en/news/275667765.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.